Novartis v Hospira — what do innovators and generics need to know?
In a robust decision handed down by the English Court of Appeal, Novartis has been awarded an interim injunction against Hospira to prevent sales of generic zoledronic acid in the UK despite Novartis’s patents having been declared invalid by the English High Court. The revocation proceedings are expected to reach the Court of Appeal some […]